XBP1 and malignant colon neoplasm: The activities of different memory cell subsets were specifically enhanced after lenalidomide treatment in XBP1-CTL (n=3) against breast cancer (MDA-MB231; Figure 4B), pancreatic cancer (Panc1; Figure 4C) and colon cancer (SW480; Figure 4D) cells.